EMPLOYMENT AGREEMENTEmployment Agreement • November 14th, 2017 • GT Biopharma, Inc. • Pharmaceutical preparations • Delaware
This Employment Agreement (the “Agreement”) is made and entered into by and among GT Biopharma, Inc. (the "Parent"), Georgetown Translational Pharmaceuticals, Inc. (the “Subsidiary” and together with the Parent, the “Companies” and each, a “Company”) and Raymond Urbanski ("Executive") as of ______________(the "Effective Date").
WARRANT EXERCISE AGREEMENTWarrant Exercise Agreement • November 14th, 2017 • GT Biopharma, Inc. • Pharmaceutical preparations • New York
This Warrant Exercise Agreement (this “Agreement”) is entered into as of August 29, 2017, by and among GT Biopharma, Inc., a Delaware corporation (the “Company”), and the parties listed on Schedule A hereto (the “Warrant Holders” or Holders”).
PREFERRED STOCK EXCHANGE AGREEMENTPreferred Stock Exchange Agreement • November 14th, 2017 • GT Biopharma, Inc. • Pharmaceutical preparations • New York
This Preferred Stock Exchange Agreement (this “Agreement”) is entered into as of August 29, 2017, by and among GT Biopharma, Inc., a Delaware corporation (the “Company”), and the parties listed on Schedule A hereto.
AMENDMENT AGREEMENTAmendment Agreement • November 14th, 2017 • GT Biopharma, Inc. • Pharmaceutical preparations • New York
This Amendment Agreement (“Agreement”) is made and entered into as of October 10, 2017, by and among GT Biopharma Inc., a Delaware corporation (the “Company”), and the parties identified on the signature page hereto (each a “Warrant Holder” and collectively, “Warrant Holders”). Capitalized terms used but not defined herein will have the meanings assigned to them in the Warrant Exercise Agreements (as defined below).
AMENDMENT AGREEMENTAmendment Agreement • November 14th, 2017 • GT Biopharma, Inc. • Pharmaceutical preparations • New York
This Amendment Agreement (“Agreement”) is made and entered into as of October 10, 2017, by and among GT Biopharma Inc., a Delaware corporation (the “Company”), and the parties identified on the signature page hereto (each a “Preferred Stockholder” and collectively, “Preferred Stockholders”). Capitalized terms used but not defined herein will have the meanings assigned to them in the Preferred Stock Exchange Agreements (as defined below).
AMENDMENT AGREEMENTAmendment Agreement • November 14th, 2017 • GT Biopharma, Inc. • Pharmaceutical preparations • New York
This Amendment Agreement (“Agreement”) is made and entered into as of October 10, 2017, by and among GT Biopharma Inc., a Delaware corporation (the “Company”), and the parties identified on the signature page hereto (each a “Note Holder” and collectively, “Note Holders”). Capitalized terms used but not defined herein will have the meanings assigned to them in the Note Conversion Agreements (as defined below).
NOTE CONVERSION AGREEMENTNote Conversion Agreement • November 14th, 2017 • GT Biopharma, Inc. • Pharmaceutical preparations • New York
This Note Conversion Agreement (this “Agreement”) is entered into as of August 29, 2017, by and among GT Biopharma, Inc., a Delaware corporation (the “Company”), and the parties listed on Schedule A hereto.
AGREEMENT AND PLAN OF MERGERAgreement and Plan of Merger • November 14th, 2017 • GT Biopharma, Inc. • Pharmaceutical preparations • Delaware
THIS AGREEMENT AND PLAN OF MERGER (“Agreement”), is entered into effective as of the 1st day of September, 2017, by and among GT Biopharma, Inc., a Delaware corporation (“GT Biopharma”), GT Biopharma Merger, Co., a Delaware corporation and a wholly-owned subsidiary of GT Biopharma (the “GT Biopharma Subsidiary”) and Georgetown Translational Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Kathleen Clarence-Smith, Mark J. Silverman, and Richard P. Dulik who are the holders of all of the issued and outstanding capital stock of the Company (the “Shareholders”).
